More than half of Ohio’s population could become eligible in June for a medical marijuana card if the state approves five more ailments as qualifying conditions.
Among the proposed additions: depression and insomnia, which affect hundreds of thousands of Ohioans.
Since January, an advisory committee for the State Medical Board of Ohio has studied the five ailments and whether medical marijuana could help. The three other conditions under consideration are anxiety, autism spectrum disorder and opioid use disorder, the formal term that the medical board uses for opioid addiction.
Tiffany Carwile of Bryan, Ohio, has a 5-year-old son with autism. She is the Ohio chapter director of Mothers Advocating Medical Marijuana for Autism. Last autumn, when the state opened a window for residents to suggest conditions to add as qualifiers, Carwile prepared a 500-page document supporting medical marijuana for autism.
“Medical marijuana is not a cure for autism. I’m not saying this is going to cure my son. But I know it’s going to dramatically improve his quality of life,” Carwile said. “If some day he can say, ‘I love you, Mom,’ I will be the happiest person in the world.” [Read more at The Cincinnati Enquirer]
Your email address will not be published. Required fields are marked *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Comment *
Notify me of follow-up comments by email.
Notify me of new posts by email.
Δ
Last year, a study came out showing that marijuana legalization in Colorado likely increased cannabis use among adults in the state. Because of the novel methods the researchers used to examine…
Last week, the U.S. Food and Drug Administration (FDA) announced that instead of approving CBD as a food or dietary supplement, it was recommending that “a new regulatory pathway for…
Many effective marketing investments aren’t available to businesses in the cannabis industry, so marketers have to get creative when it comes to building brand awareness, jumpstarting word-of-mouth, and generating leads…
At the end of 2022 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) held its first ‘technical expert meeting’ on hexahydrocannabinol, better known as HHC. This new substance, said to produce similar…